Treatment of oral cancers using iridium-192 interstitial irradiation.
OBJECTIVE
To assess retrospectively the outcome and morbidity of Iridium-192 brachytherapy in the treatment of oral cancers.


METHODS
Retrospective audit of cases treated between 1981 and 1991.


METHODS
Newcastle upon Tyne, England.


METHODS
73 patients with oral cancer treated with Iridium-192.


METHODS
Local control, crude and cause specific survival, and local morbidity.


RESULTS
Seventy four cases of squamous cell carcinoma of the oral cavity were treated using interstitial Iridium-192. The disease specific 5-year survival rates were 69% for T1, 67% for T2, and 0% for T3 tumours. Mortality from recurrent cancer was 20%, and from intercurrent disease was 28%. The incidence of major radiation induced morbidity was 11%, and the local control rate was 81% for T1, 69% for T2, and 50% for T3 tumours.


CONCLUSIONS
Interstitial radiotherapy remains a viable and valuable mode of treatment for a small proportion of patients presenting with early (T1 and T2) oral cancers.
Podd
T J
TJ
Radiotherapy Department, Newcastle General Hospital, Newcastle upon Tyne.
Carton
A T
AT
Barrie
R
R
Dawes
P K
PK
Roberts
J T
JT
Stassen
L F
LF
Henderson
R
R
Macleod
R L
RL
Piggot
T A
TA
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy* / Q000556:secondary; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome
D007496:Iridium Radioisotopes